An open label randomized controlled trial on the preemptive risedronate intervention for glucocorticoid-induced osteoporosis in chronic kidney disease patients
Not Applicable
- Conditions
- Glucocorticoid-induced osteoporosis in CKD patients
- Registration Number
- JPRN-C000000387
- Lead Sponsor
- Department of Nephrology, Osaka University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Patients receiving specific treatments that affect bone and mineral metabolism such as SERM, HRT, calcitonin, recombinant human PTH, and other bisphosphonate, except for active vitamin D. Patients in or expecting pregnancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in bone mineral density at one year interval
- Secondary Outcome Measures
Name Time Method Changes in bone turnover markers, PTH, and indices of renal function. Safety. Compliance